Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: An analysis of the PRIMROSE 1 & 2 trials

To study the timing of the effect of linzagolix, an oral GnRH antagonist, on significant reduction in heavy menstrual bleeding (HMB) in women with uterine fibroids. The study used pooled data from PRIMROSE1 and PRIMROSE2, two double-blind, similar placebo-controlled trials of linzagolix in US and Eu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fertility and sterility 2025-01
Hauptverfasser: Donnez, Jacques, Becker, Christian, Mangler, Mandy, Paszkowski, Maciej, Paszkowski, Tomasz, St-Pierre, Julien, Ionescu-Ittu, Raluca, Boolell, Mitra, Bestel, Elke, Hori, Satoshi, Petraglia, Felice
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To study the timing of the effect of linzagolix, an oral GnRH antagonist, on significant reduction in heavy menstrual bleeding (HMB) in women with uterine fibroids. The study used pooled data from PRIMROSE1 and PRIMROSE2, two double-blind, similar placebo-controlled trials of linzagolix in US and Europe, respectively. Eligible participants were randomized equally across four treatment arms (linzagolix 100mg and 200mg, with and without concomitant hormonal add-back therapy [ABT] consisting of 1 mg estradiol and 0.5 mg norethisterone acetate) and one placebo arm. The cumulative incidence of achieving clinically significant HMB reduction and maintaining it to week 24 was compared between the linzagolix arms and the placebo arm using Kaplan-Meier plots adjusted for confounding by race and study (PRIMROSE1 vs PRIMROSE2). The PRIMROSE trials randomized 1,012 women aged ≥18 years with ultrasound-confirmed uterine fibroids and HMB. Linzagolix (100mg and 200mg, with and without hormonal add-back therapy) versus placebo. The main outcome of this analysis was the time to achievement of clinically significant HMB reduction and its maintenance up to week 24. The onset of action in achieving and maintaining clinically significant HMB reduction was significantly more rapid for the linzagolix treatment arms than for the placebo arm, with a median time of
ISSN:0015-0282
1556-5653
1556-5653
DOI:10.1016/j.fertnstert.2024.12.031